Shulman Joseph 4
4 · RHYTHM PHARMACEUTICALS, INC. · Filed Feb 13, 2026
Research Summary
AI-generated summary of this filing
Rhythm Pharmaceuticals (RYTM) CTO Joseph Shulman Receives RSU Award
What Happened
Joseph Shulman, Chief Technical Officer of Rhythm Pharmaceuticals (RYTM), was granted two awards of restricted stock units (RSUs) on February 11, 2026 totaling 37,500 RSUs (15,000 + 22,500). Both grants are recorded at $0.00 (no immediate cash outlay or sale); as RSUs they are contingent rights to receive shares in the future rather than current share purchases.
Key Details
- Transaction date: February 11, 2026; filing date (Form 4): February 13, 2026 (appears timely).
- Grants: 15,000 RSUs and 22,500 RSUs, acquisition code A, reported at $0.00 (derivative awards). Total granted = 37,500 RSUs.
- Shares owned after transaction: not provided in the data you supplied.
- Footnotes:
- F1: Each RSU = contingent right to one share of common stock.
- F2: RSUs vest 25% on each of Feb 1, 2027; Feb 1, 2028; Feb 1, 2029; and Feb 1, 2030; RSUs have no expiration date.
- F3: The filing also notes stock options granted on Feb 11, 2026 that vest in 16 substantially equal installments following each three-month period of service (i.e., quarterly vesting over ~4 years).
Context
RSU grants are common forms of executive compensation and do not represent an immediate purchase or sale of stock. They generally convert into actual shares only as they vest according to the schedule above. This filing documents the grant of contingent equity awards rather than a market trade; it is informational about potential future share issuance to the executive.
Insider Transaction Report
- Award
Restricted Stock Units
[F1][F2]2026-02-11+15,000→ 15,000 total→ Common Stock (15,000 underlying) - Award
Stock Options (Right to Buy)
[F3]2026-02-11+22,500→ 22,500 totalExercise: $98.47Exp: 2036-02-10→ Common Stock (22,500 underlying)
Footnotes (3)
- [F1]Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
- [F2]The restricted stock units vest as to 25% of the total shares on each of February 1, 2027, February 1, 2028, February 1, 2029 and February 1, 2030. The restricted stock units have no expiration date.
- [F3]The stock options were granted on February 11, 2026. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.